Fasenra® (benralizumab)

Covered: Fasenra (benralizumab) is covered as add‑on maintenance therapy for FDA‑labeled severe eosinophilic asthma in patients ≥6 years (not covered for <6 years or non‑eosinophilic asthma), with dosing per label including pediatric weight‑based dosing. Key requirements: initial approval (6 months) requires blood eosinophils ≥150 cells/µL within 6 weeks, ≥3 months of ICS plus another controller, asthma uncontrolled by specified criteria (≥2 steroid bursts or ≥1 hospitalization/ER, FEV1<80% predicted, FEV1/FVC<0.80, or steroid‑taper worsening), and prescription by/consult with an allergist/immunologist/pulmonologist; reauthorization (12 months) requires ≥6 months on Fasenra, continued ICS use, and documented clinical response.

"For pediatric patients: weight documentation to support dosing (i."

Sign up to see full coverage criteria, indications, and limitations.